DEVA Holding Çerkezköy II manufacturing facilities located at the 110 km distance to Istanbul, founded on an area of 67,551 m2 in Çerkezköy Organized Industrial Zone, with closed facilities of 21,968 m2, comprise of state-of-the-art manufacturing buildings where solid oncology, sterile liquid oncology, animal health products and APIs are manufactured.

Solid Oncology Manufacturing Area

Products in tablet and capsule form are manufactured in the solid oncology manufacturing unit.

The total manufacturing quantity, which was 653,626 units in 2019, was 1.243.887 units with a 90% increase in 2020. .
Of the total of 1.243.887 units of products manufactured in 2020, 348.964 units were capsules and 894.923 units were tablets

In addition, 131.003 of the 894.923 units of product manufactured in tablet form and 156.348 units of 348.964 capsules were produced for the European market.

Sterile Liquid Oncology Manufacturing Area

Products in sterile liquid and sterile lyophilized powder forms are manufactured in the Sterile Liquid Oncology Manufacturing unit.

The manufacturing quantity of the unit of 1.007.700 units in 2019 was 1.074.610 units in 2020 with a 7% increase.

Of the 1.074.610 units of products, liquid products comprise 838.432 units and lyophilized products comprise 236.178 units.

Sterile Animal Health Products Manufacturing Area

Products in sterile suspension and intramammary pomade form are manufactured in sterile animal health products manufacturing unit. The manufacturing quantity of the unit, which was 333,522 units in 2019, was 131.990 units in 2020.

Of the 131.990 units of product, sterile suspension products constitute 130.621 units and sterile intra-breast pomade products constitute 1.369 units. As of February 2020, this section was closed in line with the decision not to produce beta lactam products at the facility, and the products started to be produced on contract.

Non-steril Animal Health Products (Units)

7 tablet-form products, 16 large and small powder fillform products and 1 bag powder fill-form product are being produced as animal health products in tablet, powder and bag form in the non-sterile animal health products manufacturing unit.

This unit is divided into two subunits; non-betalactams and betalactams. While animal health products in tablet, powder and pouch form are manufactured in the non-betalactam unit, products in powder form are manufactured in the betalactams unit.

The production output of the unit, which was 2,411,678 units in 2019, increased to 3.792.431 units in 2020 with a 57% increase. Of these products, 3.455.270 units were tablets, and 337.161 units were powders.

API Manufacturing Areas

The facilities have four separate designated API manufacturing units: non-betalactam API, betalactam non-sterile API, betalactam sterile API, and oncolytic API.

The API manufacturing quantity, which was 14.617 kg in 2019, was 9.659 kg in 2020.

29 different APIs are produced in non-betalactam, betalactam and oncology API production areas.

Of the 9.659 kg of API produced in total in 2020, 1.914 was produced as non-betalactam, 6.990 kg as betalactam and 755 kg as oncology APIs.

In API manufacturing, the toxic gases arising from reaction are neutralized before being released to the atmosphere to minimize the environmental effects resulting from manufacturing activities.

To summarize, finished products production output in DEVA Holding A.Ş. Çerkezköy-2 facilities increased by 42% from 4.406.526 units in 2019 to 6.242.918 units in 2020.

The capacity utilization rate of Çerkezköy Main and API Manufacturing facilities is 92%.